Pasithea Therapeutics (KTTA) Long-Term Debt Issuances (2021 - 2025)

Pasithea Therapeutics (KTTA) posted Long-Term Debt Issuances of $179310.0 for Q1 2025, down 32.11% sequentially from $264103.0 in Q2 2023.

Pasithea Therapeutics (KTTA) Long-Term Debt Issuances (2021 - 2025) Analysis & Trends

Pasithea Therapeutics has reported Long-Term Debt Issuances for 3 years, with the latest figure at $179310.0 in Q1 2025.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $179310.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $443413.0 (changed N/A YoY) and the FY2023 annual result came in at $392354.0, changed N/A from the prior year.
Long-Term Debt Issuances eased to $179310.0 in Q1 2025 per KTTA's latest filing, from $264103.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $20.7 million in Q3 2021 and troughed at $128251.0 in Q1 2023.
A 3-year average of $4.6 million and a median of $736514.5 in 2021 frame the typical range for Long-Term Debt Issuances.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Pasithea Therapeutics	16.97 Mn	16.97 Mn	-	-

Download Data